Target: Beta Synuclein
Nature: Recombinant
Swiss-Prot: Q16143
Expression System: E. coli
Protein Length: Full length
Purification: Ion-exchange Purified
Purity: >95%
Storage Buffer: PBS pH 7.4
Protein Size: 14.28 kDa
Conjugate: No tag
Cellular Localization: Cytoplasm
Scientific Background: Alzheimer’s Disease (AD) is the most common neurodegenerative disease, affecting 10% of seniors over the age of 65 (1). It was named after Alois Alzheimer, a German scientist who discovered tangled bundles of fibrils where neurons had once been in the brain of a deceased patient in 1907 (2). Beta synuclein is abundant in neurofibrillary lesions of patients with Alzheimer's Disease. Beta synuclein is suggested to be an inhibitor of alpha synuclein aggregation- protecting the central nervous system from the neurotoxin effects of alpha synuclein (3).
References: 1. www.alz.org/alzheimers-dementia/facts-figures2. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 64, 146–148 (1907). 3. Taschenberger G., et al. (2013) Ann Neurol. 74(1): 109-118.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.
English
Deutsch
